Tilray Brands (TLRY.TO) subsidiary Tilray Medical said Thursday its medical cannabis edibles called Good Supply Pastilles are now available to patients in Australia.

The launch marks Tilray Medical's first medical cannabis edible offering in the country, providing patients with a sugar-free and vegan-friendly treatment option, the company said.

"Our dedication to innovation and patient care drives us to continuously expand our offerings, ensuring that patients receive the best possible treatment options tailored to meet their needs and preferences," said Denise Faltischek, chief strategy officer and head of international at Tilray Brands.

Earlier Thursday, Tilray said that it is seeking stockholder approval for its plan to implement a reverse stock split at a ratio ranging from 1-to-10 to 1-to-20. Stockholders will vote on the proposal at a special meeting scheduled for June 10.

"The reverse stock split will better align Tilray's number of shares outstanding with companies of our size and scope," said Irwin Simon, Tilray's chairman and CEO. "A higher price per share would ensure compliance with Nasdaq's continued listing requirements and places Tilray in a position to continue executing on our strategic plans."

Tilray said it also expects to achieve cost savings from the planned reverse stock split, which would reduce the company's expenditures associated with its annual meeting.

Tilray's share price closed 2.9% lower on Wednesday to $0.66 on the TSX.